IPSC-derived CAR-NK cells for cancer immunotherapy

被引：40

作者：

Lin, Xiaotong ^{[1
,2
]}

Sun, Yao ^{[1
]}

Dong, Xin ^{[1
]}

Liu, Zishen ^{[1
,2
]}

Sugimura, Ryohichi ^{[3
]}

Xie, Guozhu ^{[1
,2
]}

机构：

[1] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Peoples R China

[2] Southern Med Univ, Sch Clin Med 1, Guangzhou 510515, Peoples R China

[3] Univ Hong Kong, Ctr Translat Stem Cell Biol, Sch Biomed Sci, Pokfulam, Hong Kong, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2023年 / 165卷

关键词：

Chimeric antigen receptor; Induced pluripotent stem cell; Natural killer cell; Immunotherpy; NATURAL-KILLER-CELLS; CHIMERIC ANTIGEN RECEPTOR; PLURIPOTENT STEM-CELLS; T-CELLS; ADOPTIVE TRANSFER; THERAPY; MOUSE; ACTIVATION; STROMA; BINDS;

D O I：

10.1016/j.biopha.2023.115123

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Adoptive cell therapies (ACT) based on chimeric antigen receptor (CAR)-modified immune cells have made great progress with six CAR-T cell products approved by the U.S. FDA for hematological malignancies. Compared with CAR-T cells, CAR-NK cells have attracted increasing attention owing to their multiple killing mechanisms, higher safety profile, and broad sources. Induced pluripotent stem cell (iPSC)-derived NK (iPSC-NK) cells possess a mature phenotype and potent cytolytic activity, and can provide a homogeneous population of CAR-NK cells that can be expanded to clinical scale. Thus, iPSC-derived CAR-NK (CAR-iNK) cells could be used as a standardized and "off-the-shelf" product for cancer immunotherapy. In this review, we summarize the current status of the manufacturing techniques, genetic modification strategies, preclinical and clinical evidence of CAR-iNK cells, and discuss the challenges and future prospects of CAR-iNK cell therapy as a novel cellular immunotherapy in cancer.

引用

页数：11

共 103 条

[1] The multifaceted role of TRAIL signaling in cancer and immunity [J].

Alves, Ludmila Cardoso ;

Corazza, Nadia ;

Micheau, Olivier ;

Krebs, Philippe .

FEBS JOURNAL, 2021, 288 (19) :5530-5554

[2] Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].

Andre, Pascale ;

Denis, Caroline ;

Soulas, Caroline ;

Bourbon-Caillet, Clarisse ;

Lopez, Julie ;

Arnoux, Thomas ;

Blery, Mathieu ;

Bonnafous, Cecile ;

Gauthier, Laurent ;

Morel, Ariane ;

Rossi, Benjamin ;

Remark, Romain ;

Breso, Violette ;

Bonnet, Elodie ;

Habif, Guillaume ;

Guia, Sophie ;

Lalanne, Ana Ines ;

Hoffmann, Caroline ;

Lantz, Olivier ;

Fayette, Jerome ;

Boyer-Chammard, Agnes ;

Zerbib, Robert ;

Dodion, Pierre ;

Ghadially, Hormas ;

Jure-Kunkel, Maria ;

Morel, Yannis ;

Herbst, Ronald ;

Narni-Mancinelli, Emilie ;

Cohen, Roger B. ;

Vivier, Eric .

CELL, 2018, 175 (07) :1731-+

[3] Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells [J].

Angelos, Mathew G. ;

Ruh, Paige N. ;

Webber, Beau R. ;

Blum, Robert H. ;

Ryan, Caitlin D. ;

Bendzick, Laura ;

Shim, Seonhui ;

Yingst, Ashley M. ;

Tufa, Dejene M. ;

Verneris, Michael R. ;

Kaufman, Dan S. .

BLOOD, 2017, 129 (26) :3428-3439

[4]

[Anonymous], 2021, CENT THER ANN DAT 63

[5] Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial [J].

Arai, S. ;

Meagher, R. ;

Swearingen, M. ;

Myint, H. ;

Rich, E. ;

Martinson, J. ;

Klingemann, H. .

CYTOTHERAPY, 2008, 10 (06) :625-632

[6] Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma [J].

Bachanova, Veronika ;

Ghobadi, Armin ;

Patel, Krish ;

Park, Jae H. ;

Flinn, Ian W. ;

Shah, Prutha ;

Wong, Carol ;

Bickers, Cara ;

Szabo, Peter ;

Wong, Lilly ;

Valamehr, Bahram ;

Atwal, Siminder ;

Chu, Yu-Waye ;

Elstrom, Rebecca ;

Strati, Paolo .

BLOOD, 2021, 138

[7] cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications [J].

Baghbaderani, Behnam Ahmadian ;

Tian, Xinghui ;

Neo, Boon Hwa ;

Burkall, Amy ;

Dimezzo, Tracy ;

Sierra, Guadalupe ;

Zeng, Xianmin ;

Warren, Kim ;

Kovarcik, Don Paul ;

Fellner, Thomas ;

Rao, Mahendra S. .

STEM CELL REPORTS, 2015, 5 (04) :647-659

[8] The Natural Cytotoxicity Receptors in Health and Disease [J].

Barrow, Alexander David ;

Martin, Claudia Jane ;

Colonna, Marco .

FRONTIERS IN IMMUNOLOGY, 2019, 10

[9] CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma [J].

Bexte, Tobias ;

Alzubi, Jamal ;

Reindl, Lisa Marie ;

Wendel, Philipp ;

Schubert, Ralf ;

Salzmann-Manrique, Emilia ;

von Metzler, Ivana ;

Cathomen, Toni ;

Ullrich, Evelyn .

ONCOIMMUNOLOGY, 2022, 11 (01)

[10] FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma [J].

Bjordahl, Ryan ;

Gaidarova, Svetlana ;

Goodridge, Jode P. ;

Mahmood, Sajid ;

Bonello, Greg ;

Robinson, Megan ;

Ruller, Chelsea ;

Pribadi, Mochtar ;

Lee, Tom ;

Abujarour, Ramzey ;

Dinella, Jason ;

Huffman, Janel ;

Chu, Hui-yi ;

Hopken, Uta ;

Rehm, Armin ;

Valamehr, Bahram .

BLOOD, 2019, 134

← 1 2 3 4 5 6 7 8 9 10 →